Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine

Sponsor
Duke University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05340322
Collaborator
United States Agency for International Development (USAID) (U.S. Fed), Universidad Peruana Cayetano Heredia (Other)
1,000
1
1
34
29.4

Study Details

Study Description

Brief Summary

The Pocket colposcope has 510k FDA clearance and has been successfully used in almost 1500 unique patients globally in Duke and non-Duke protocols to date. The objective is to provide colposcopy capability to rural communities in Peru potentially using Telehealth. Approximately 10,000 women will receive self HPV test kit for community health workers. Of these participants, approximately 1,000 HPV+ participants will be invited to participate in this pocket colposcopy study. Approximately 500 of these participants may require treatment using thermocoagulation.

Condition or Disease Intervention/Treatment Phase
  • Device: Colposcopy using pocket colpscope and thermocoagulator
N/A

Detailed Description

The goal is to demonstrate that the combination of self-sampling, the Pocket colposcope and the thermocoagulator will yield a high proportion of HPV positive women who complete treatment and follow-up care. The bulk of this trial will occur over a two-year period in Peru. Duke will provide the Pocket colposcope and the Calla application to run the device only. Dr. Garcia will recruit and train community women for the distribution of self-collection HPV test kits, identify and partner with 10 to 12 health centers in the Andean region of Peru, conduct baseline data collection in each health center, procure necessary equipment and technology, and conduct training for HPV testing, Pocket colposcopy, and thermocoagulation. Within 18 months trained community women will distribute 10,000 HPV tests to women within the region. The investigators anticipate that 10% of the women screened will be HPV positive and they will be recruited for our trial. As part of the study the participants will be followed to determine if the participants attend a health center, receive Pocket colposcopy, and if needed whether the participants are treated with the thermocoagulator device. All women will be appointed to return to the health center for a follow-up evaluation six months post-treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Closing the Gap Between Identification and Treatment of Cervical Abnormalities in Lima, Perú Through Integraton of Pocket Colposcopy, Telemedicine and Visual Counseling
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: HPV+ Pap smear

Visualization of cervix and if abnormalities are present treat with SOC thermocoagulation.

Device: Colposcopy using pocket colpscope and thermocoagulator
If HPV+, visualization with pocket colposcope and treatment with thermocoagulator

Outcome Measures

Primary Outcome Measures

  1. Number of HPV+ women examined [up to 2 years]

    Total number of HPV positive women that went to a Peruvian health center for treatment and were examined using the Pocket Colposcope

Secondary Outcome Measures

  1. Proportion of HPV positive women who completed the 6 month follow-up after evaluation and treatment. [6 months after initial visit]

    Proportion of participants of HPV+ women who completed the 6 month follow-up visit after evaluation and treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 49 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • HPV+ pap smear

  • Women must between the ages of 30-49yo

Exclusion Criteria:
  • HPV (-) pap smear

  • people without a cervix

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universidad Peruana Cayetano Heredia Lima Peru

Sponsors and Collaborators

  • Duke University
  • United States Agency for International Development (USAID)
  • Universidad Peruana Cayetano Heredia

Investigators

  • Principal Investigator: Nimmi Ramanujam, Ph.D., Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT05340322
Other Study ID Numbers:
  • Pro00106490
First Posted:
Apr 22, 2022
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Duke University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022